These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 6420517

  • 1. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
    Birkmayer W, Birkmayer G, Lechner H, Riederer P.
    J Neural Transm; 1983; 58(3-4):305-13. PubMed ID: 6420517
    [Abstract] [Full Text] [Related]

  • 2. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, Taylor MD.
    Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
    [Abstract] [Full Text] [Related]

  • 3. Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine.
    Ogawa N, Kuroda H, Yamamoto M, Nukina I, Ota Z.
    Acta Med Okayama; 1984 Jun; 38(3):301-4. PubMed ID: 6431755
    [Abstract] [Full Text] [Related]

  • 4. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
    Sakoda S, Suzuki T, Higa S, Ueji M, Kishimoto S, Matsumoto M, Yoneda S.
    Eur Neurol; 1985 Jun; 24(5):330-4. PubMed ID: 3932074
    [Abstract] [Full Text] [Related]

  • 5. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
    Yamamoto M, Ogawa N, Ujike H.
    J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714
    [Abstract] [Full Text] [Related]

  • 6. The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance.
    Tanaka H, Yamaguchi H, Mino M.
    Clin Auton Res; 1996 Aug; 6(4):189-93. PubMed ID: 8902314
    [Abstract] [Full Text] [Related]

  • 7. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
    Hoeldtke RD, Cilmi KM, Mattis-Graves K.
    Clin Pharmacol Ther; 1984 Sep; 36(3):302-6. PubMed ID: 6432398
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R.
    Circulation; 2003 Aug 12; 108(6):724-8. PubMed ID: 12885750
    [Abstract] [Full Text] [Related]

  • 12. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
    Ogawa N, Yamamoto M, Takayama H.
    J Med; 1985 Aug 12; 16(5-6):525-34. PubMed ID: 3938472
    [Abstract] [Full Text] [Related]

  • 13. Orthostatic hypotension in familial amyloid polyneuropathy: treatment with DL-threo-3,4-dihydroxyphenylserine.
    Suzuki T, Higa S, Sakoda S, Hayashi A, Yamamura Y, Takaba Y, Nakajima A.
    Neurology; 1981 Oct 12; 31(10):1323-6. PubMed ID: 6287350
    [Abstract] [Full Text] [Related]

  • 14. Improved orthostatic tolerance in familial amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine.
    Carvalho MJ, van den Meiracker AH, Boomsma F, Man in 't Veld AJ, Freitas J, Costa O, de Freitas AF.
    J Auton Nerv Syst; 1997 Jan 12; 62(1-2):63-71. PubMed ID: 9021651
    [Abstract] [Full Text] [Related]

  • 15. Effect of long-term L-threo-3,4-dihydroxyphenylserine administration on alpha 2-adrenergic receptors in platelet membranes in neurologic disorders.
    Azuma T, Suzuki T, Sakoda S, Mizuno R, Tsujino S, Kobayashi T, Kishimoto S, Hiraga T, Matsubara T, Yoshida S.
    Acta Neurol Scand; 1991 Jul 12; 84(1):46-50. PubMed ID: 1656690
    [Abstract] [Full Text] [Related]

  • 16. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.
    Freeman R, Landsberg L, Young J.
    Neurology; 1999 Dec 10; 53(9):2151-7. PubMed ID: 10599797
    [Abstract] [Full Text] [Related]

  • 17. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
    Hauser RA, Hewitt LA, Isaacson S.
    J Parkinsons Dis; 2014 Dec 10; 4(1):57-65. PubMed ID: 24326693
    [Abstract] [Full Text] [Related]

  • 18. Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine.
    Suzuki T, Sakoda S, Ueji M, Kishimoto S.
    Life Sci; 1985 Feb 04; 36(5):435-42. PubMed ID: 3918223
    [Abstract] [Full Text] [Related]

  • 19. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
    Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G.
    Mov Disord; 2015 Apr 15; 30(5):646-54. PubMed ID: 25487613
    [Abstract] [Full Text] [Related]

  • 20. Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.
    Gupta F, Karabin B, Mehdirad A.
    Clin Auton Res; 2017 Jul 15; 27(Suppl 1):15-16. PubMed ID: 28699047
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.